Dernière mise à jour :
19/11/2024
Antiarythmique   Metoprolol tartrate  
injectable
Solution buvable
Stabilité des solutions Stabilité en mélange Facteur influençant la stabilité Compatibilités Voie d’administration Bibliographie pdf
   Structure chimique  

Noms commerciaux   Noms commerciaux     

Les noms commerciaux sont donnés à titre indicatif et la composition en excipients peut être différente selon les pays et selon les laboratoires

Beloc Autriche, Suisse, Turquie
Beloken Espagne
Betaloc Grande Bretagne, Pologne
Lopresor Canada
Selokeen Pays bas
Seloken Belgique, Brésil, Danemark, Finlande, Italie, Norvège, Suède
Bibliographie   injectable   Bibliographie : Metoprolol tartrate  
Type Source
62 Revue Pugh CB, Pabis DJ, Rodriguez C.
Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 123-125.
238 Revue Belliveau PP, Shea BF, Scavone JM.
Stability of metoprolol tartrate in 5% dextrose injection or 0.9% sodium chloride injection.
Am J Hosp Pharm 1993 ; 50: 950-952.
240 Revue Lam XM, Ward CA, de C du M?e CPR.
Stability and activity of alteplase with injectable drugs commonly used in cardiac therapy.
Am J Health-Syst Pharm 1995 ; 52: 1904-1909.
921 Revue Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
1944 Revue Hartman CA, Faria CE, Mago K.
Visual compatibility of bivalirudin with selected drugs.
Am J Health-Syst Pharm 2004 ; 61: 1774.
1964 Revue Hartman CA, Baroletti SA, Churchill WW et al.
Visual compatibility of argatroban with selected drugs.
Am J Health-Syst Pharm 2002 ; 59: 1784-1785.
2267 Revue Kraft MD, Johnson CE, Chung C, Julian F.
Stability of metoprolol tartrate injection 1 mg/ml undiluted and 0.5 mg/ml in 0.9% sodium chloride injection and 5% dextrose injection.
Am J Health-Syst Pharm 2008 ; 65, 7: 636-638.
2269 Revue Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2346 Revue Newland A.M, Mauro V.F, Alexander K.S.
Physical compatibility of metoprolol tartrate injection with selected cardiovascular agents
Am J Health-Syst Pharm 2009 ; 66: 986-987.
3249 Revue Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3372 Revue Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S.
Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine.
Rev Bras Anestesiol 2013 ; 63, 1: 163-166.
3538 Revue Gilcher Th, Heeb R M, Krämer I.
Physikalisch-chemische Stabilität einer Metoprolol-Injektionslösung 1 mg/ml, 50 ml.
Krankenhauspharmazie 2013 ; 11: 524-525.
3644 Laboratoire Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010
3838 Laboratoire Magnesium Sulphate - Summary of Product Characteristics
Martindale Pharmaceuticals Ltd 2007
3879 Revue Foushee Jaime A, Meredith Pmichaele, Fox Laura M, Grace Edward E.
Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures.
Int J Pharm Compound 2016 ; 20, 4 : 328-332.
3934 Laboratoire Eptifibatide (Integrilin®) - Résumé des caractéristiques du produit
GlaxoSmithKline Laboratoire 2016
4319 Revue Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.
Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.
Hosp Pharm 2020 ; 55, 5: 332-337.
4433 Revue Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K.
Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications
Clin Ther 2020 ; 42, 3: 475-485.

  Mentions Légales